TARGETED T CELLS AGAINST HEMATOPOIETIC CELLS EXPRESSING ONCOGENIC CALRETICULIN MUTANTS

EHA Library, Robert Kralovics, 419095

IMPACT OF TP53 MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DURING ORAL AZACITIDINE MAINTENANCE THERAPY: OUTCOMES FROM THE QUAZAR AML-001 TRIAL

EHA Library, Andrew H. Wei, 420624

GILTERITINIB PLUS VENETOCLAX, LOW-DOSE CYTARABINE, AND ACTINOMYCIN D AS FIRST SALVAGE THERAPY FOR RELAPSED OR REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Andrius Žučenka, 420625

PRELIMINARY SAFETY AND ANTILEUKEMIC ACTIVITY OF SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Pau Montesinos, 420626

VENETOCLAX AND HYPOMETHYLATING AGENTS COMPARED TO OTHER STRATEGIES IN OLDER ACUTE MYELOID LEUKAEMIA PATIENTS IN THE REAL LIFE. A RETE EMATOLOGICA LOMBARDA (REL) STUDY

EHA Library, Erika Borlenghi, 420627

EFFICACY OF VENETOCLAX-BASED INDUCTION REGIMEN IN NEWLY DIAGNOSED PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, Xiaojia Wen, 420628

FLAG REGIMEN, COMBINED WITH GEMTUZUMAB (FLAG-GO) RESULTS IN BETTER OPTIMAL MOLECULAR RESPONSE AND OUTCOMES, COMPARED TO COMBINATION WITH IDARUBICIN (FLAG-IDA) IN UNTREATED CORE BINDING FACTOR AML

EHA Library, Gautam Borthakur, 420629

ROLE OF MRD AS A BIOMARKER TO OPTIMIZE OUTCOME IN ELN2017 INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: COMPARISON BETWEEN GIMEMA AML1310 MRD-DRIVEN PROTOCOL AND REAL-LIFE DECISION-MAKING PROCESS.

EHA Library, Raffaele Palmieri, 420630

VENETOCLAX-AZACITIDINE VERSUS AZACITIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN FIRST RELAPSE OR PRIMARY REFRACTORY TO INTENSIVE CHEMOTHERAPY. AN IPC-DATAML-MSKCC STUDY

EHA Library, Sylvain Garciaz, 420631

OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS WITHIN THE LAST 25 YEARS, A SINGLE CENTER EXPERIENCE

EHA Library, Claudia Roggenbuck, 420632

A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE RISK OF SECOND PRIMARY MALIGNANCIES IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS TREATED WITH ARSENIC TRIOXIDE

EHA Library, Ming-Hsien Lin, 420633

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY AS CONSOLIDATION TREATMENT FOR ACUTE MYELOID LEUKEMIA IN FIRST REMISSION: A PETHEMA REGISTRY STUDY.

EHA Library, Ana ALFONSO PIEROLA, 420634

REAL-WORLD USE OF ORAL-AZACITIDINE AS MAINTENANCE THERAPY FOR ACUTE MYELOID LEUKEMIA IN REMISSION: CHARACTERISTICS AND OUTCOMES OF A FRENCH PATIENT POPULATION

EHA Library, Christian Récher, 420635

QUANTUM-FIRST: PATIENT-REPORTED OUTCOMES (PROS) IN NEWLY DIAGNOSED (ND) FLT3-ITD+ ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS) RECEIVING STANDARD CHEMOTHERAPY (CTX) PLUS QUIZARTINIB (Q) OR PLACEBO (P)

EHA Library, Esther N. Oliva, 420636

PROGNOSTIC RELEVANCE OF TP53 MUTATIONS WITH OR WITHOUT CONCOMITANT COMPLEX KARYOTYPE IN PATIENTS TREATED WITH CPX-351: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY.

EHA Library, Elisabetta Todisco, 420637

NUP98 FUSIONS IN ADULT AML: A COHORT ANALYSIS ON FREQUENCY, CO-MUTATIONS AND GENETIC IDENTIFICATION OF A NOVEL FUSION PARTNER

EHA Library, James Heald, 420638

RESULTS OF THE PETHEMA PEVOLAM TRIAL: A PHASE III RANDOMIZED OPEN LABEL STUDY COMPARING AZACITIDINE PLUS PEVONEDISTAT VERSUS AZACITIDINE IN UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Rebeca Rodriguez Veiga, 420639

PROGNOSTIC IMPLICATIONS OF MEASURABLE RESIDUAL DISEASE AND KIT MUTATION IN PEDIATRIC CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA

EHA Library, TINGCHI YEH, 420640

PRELIMINARY RESULTS OF THE FRIDA STUDY:  IADADEMSTAT AND GILTERITINIB IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA.

EHA Library, Amir Fathi, 420641

MUTATIONAL PATTERNS AND CLONAL HIERARCHY IN 430 PATIENTS WITH IDH1 MUTATED AML INDICATE PRACTICAL IMPLICATIONS FOR MOLECULAR TESTING AND TARGETED TREATMENT

EHA Library, Gregor Hoermann, 420642

CHARACTERISTICS AND OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA CHARACTERIZED BY ISOLATED TRISOMIES AS COMPARED TO COMPLEX KARYOTYPES ACCORDING TO DIFFERENT TREATMENT STRATEGIES

EHA Library, Sabine Kayser, 420643

A MULTICENTER REAL-WORLD ANALYSIS OF GEMTUZUMAB OZOGAMICIN IN THE FIRST-LINE TREATMENT OF CBF-AML

EHA Library, Philippe J. Muller, 420644

LIPOSOMAL CYTARABINE AND DAUNORUBICIN (CPX-351) VERSUS INTENSIVE INDUCTION CHEMOTHERAPY IN PATIENTS WITH THERAPY-RELATED AML OR AML WITH MDS-RELATED CHANGES: A COMPARATIVE HOVON-SAKK ANALYSIS

EHA Library, Dimitrios Kotsos, 420645

A PHASE 1, DOSE-ESCALATION STUDY OF QLF32101, A CLL1/CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Jianxiang Wang, 420646

GENETIC PROGNOSTIC SCORING SYSTEM FOR AML WITH MYELODYSPLASIA-RELATEDABNORMALITIES

EHA Library, Yijing Zhao, 420647

A NON-INTERVENTIONAL COHORT STUDY INVESTIGATING THE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: SECOND INTERIM RESULTS

EHA Library, Cristina Papayannidis, 420648

GENOMIC PROFILES AND CLINICAL OUTCOMES IN DE NOVO VERSUS THERAPY-RELATED CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA (AML) AND OUTCOMES PREDICTORS

EHA Library, May Chiu, 420649

THE STABILITY AND CLINICAL IMPACT OF MEASURABLE RESIDUAL DISEASE BY REAL-TIME QUANTITATIVE PCR FOR KMT2A PARTIAL TANDEM DUPLICATION IN ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Hsiao-Wen Kao, 420650

BRAF DELETION IN ADULT PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS CORRELATES WITH MULTISYSTEM DISEASE AND POOR OUTCOME

EHA Library, Min Lang, 420651

QUALITY OF LIFE BENEFITS OF ATO VS CHEMOTHERAPY IN PATIENTS WITH APL ARE SUSTAINED OVER TIME: RESULTS FROM THE GIMEMA APL0406

EHA Library, Fabio Efficace, 420652

QUANTUM-FIRST: EFFICACY BY AGE IN NEWLY DIAGNOSED (ND) PATIENTS (PT) WITH FMS-LIKE TYROSINE KINASE 3-INTERNAL TANDEM DUPLICATION–POSITIVE (FLT3-ITD+) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Pau Montesinos, 420653

REDUCED VENETOCLAX EXPOSURE TO 7 DAYS VS STANDARD VENETOCLAX EXPOSURE WITH HYPOMETHYLATING AGENT IN OLDER/UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COMPARISON.

EHA Library, Christophe Willekens, 420654

REAL-WORLD EXPERIENCE WITH CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: UPDATED ANALYSIS OF THE CANCER ANALYSIS SYSTEM DATABASE

EHA Library, Alexandrina Lambova, 420655

A RANDOMIZED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS): A SUBGROUP ANALYSIS OF UK NCRI AML19

EHA Library, Alex Legg, 420656

TREATMENT PATTERNS AND CLINICAL OUTCOMES IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WITH AND WITHOUT MIDH1/MIDH2 TREATED WITHOUT INTENSIVE CHEMOTHERAPY: REAL-IDH A STUDY OF REAL WORLD DATABASES

EHA Library, Christian Récher, 420657

FLAVIDA CHEMOTHERAPY IS AN EFFECTIVE BRIDGE-TO-TRANSPLANT STRATEGY IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Rabia Shahswar, 420659

HIGH RISK MUTATIONS IN CRITICAL GENES DO NOT AFFECT REMISSION RATES AND MRD CLEARANCE IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CPX-351 INDUCTION

EHA Library, Carola Riva, 420660

PREDICTORS OF EARLY MORTALITY IN 1,073 PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA BASED ON THE 2022 INTERNATIONAL CONSENSUS CLASSIFICATION

EHA Library, Hsin-Yu Lu, 420661

CLINICAL CHARACTERISTICS OF RARE GENETIC ALTERATIONS ASSOCIATED WITH UPREGULATION OF HOX GENES IN ADULTS WITH ACUTE LEUKEMIA

EHA Library, Aziz Farhat, 420662

MUTATION PATTERNS AND PROGNOSTIC IMPLICATIONS IN ACUTE MYELOID LEUKEMIA WITH CHROMOSOMAL 7 DELETIONS

EHA Library, Eitan Kugler, 420663

RVU120, A FIRST-IN-CLASS CDK8 INHIBITOR FOR THE TREATMENT OF RELAPSED/REFRACTORY AML AND HIGH-RISK MDS: PRELIMINARY RESULTS FROM TWO ONGOING STUDIES

EHA Library, Dominik Chraniuk, 420664

INTERIM ANALYSIS OF A RANDOMIZED PHASE 1 TRIAL IN HEALTHY VOLUNTEERS INVESTIGATING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL FLT3/IRAK4 INHIBITOR, LOMONITINIB (ZE46-0134)

EHA Library, John C. Byrd, 420665

REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR ACUTE MYELOID LEUKEMIA: A SHORT-TERM ANALYSIS OF EFFICACY AND SAFETY

EHA Library, Ma Jun, 420666

PHASE II STUDY OF CLADRIBINE, IDARUBICIN, AND HIGHER DOSE CYTARABINE (CLIA) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Tapan Kadia, 420667

BARRIERS TO AN ALLOGENEIC HSCT IN OLDER AML PATIENTS ACHIEVING REMISSION WITH INTENSIVE CHEMOTHERAPY: INSIGHTS FROM THE UK NCRI AML 18 TRIAL.

EHA Library, Priyanka Mehta, 420668

OLUTASIDENIB DEMONSTRATES CLINICAL ACTIVITY IN MUTATED IDH1 ACUTE MYELOID LEUKEMIA (AML) SECONDARY TO MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Stéphane De Botton, 420669

THE LEVELS OF EVI1 AND CLINICAL FEATURES HELP TO DISTINGUISH THE PROGNOSTIC HETEROGENEITY IN THE EVI1 OVEREXPRESSION AML ENTITY

EHA Library, Xiao-Hang Ma, 420670

LEUKAPHERESIS DOES NOT HAVE AN IMPACT ON EARLY MORTALITY RATE IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS

EHA Library, Mirjana Cvetkovic, 420671

THERAPEUTIC VENETOCLAX MONITORING BY MASS SPECTROMETRY TO REFINE DRUG DOSING IN AML PATIENTS

EHA Library, Sena Alptekin, 420672

REAL-WORLD EFFICACY OF VENETOCLAX-AZACITIDINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTRIC STUDY FROM THE GRUPO PORTUGUÊS DE LEUCEMIAS AGUDAS (GPLA)

EHA Library, Luis Monteiro, 420673

NEW COMBINATION REGIMENS VS FLAI IN THE TREATMENT OF INTERMEDIATE OR LOW RISK NPM1-MUTATED AML: A RETROSPECTIVE ANALYSIS FROM 7 ITALIAN CENTERS

EHA Library, Giulia Battaglia, 420674

SAFETY AND EFFICACY OF OLUTASIDENIB TREATMENT IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MIDH1 ACUTE MYELOID LEUKEMIA

EHA Library, Stéphane De Botton, 420675

RISK STRATIFICATION OF CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA WITH CEBPA-BZIP MUTATIONS BASED ON MULTI-GENE SEQUENCING

EHA Library, Mingyue Liao, 420676

THE CLINICAL IMPACT OF CONCURRENT GENE MUTATIONS AND CYTOGENETIC ABNORMALITIES ON NPM1-MUTATED AML: A RETROSPECTIVE COHORT STUDY OF 1,520 PATIENTS

EHA Library, Ting-Wei Lyu, 420677

RESPONSE TO OLUTASIDENIB IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) FOLLOWING VENETOCLAX FAILURE

EHA Library, Jorge Cortes, 420678

REAL-WORLD EXPERIENCE USING CPX-351 FOR AML-MRC AND THERAPY RELATED MYELOID NEOPLASMS.

EHA Library, Daniele Avenoso, 420679

IMPACT OF PREVIOUS CHEMOTHERAPY (CT) EXPOSURE ON  MOLECULAR CHARACTERISTICS AND TREATMENT OUTCOMES OF THERAPY RELATED MYELOID NEOPLASMS (T-MN)

EHA Library, Pinkal Desai, 420681

PRESENCE OF BONE MARROW FIBROSIS AND NECROSIS IS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Elliot Smith, 420682

COMPARING OUTCOMES BETWEEN CPX-351 AND FLUDARABINE-BASED INDUCTION IN SECONDARY OR THERAPY RELATED ACUTE MYELOID LEUKEMIA: THE PROGNOSTIC ROLE OF MRD

EHA Library, Chiara Vernarecci, 420683

PROGNOSTIC FACTORS IN TP53-MUTATED AML/MDS PATIENTS UNDERGOING ALLO-HSCT: INSIGHTS FROM A MULTI-CENTER STUDY

EHA Library, Yanmin Zhao, 420685

BURDEN OF ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES IN A LARGE OBSERVATIONAL STUDY (ILL-CAR-2018-01) ON LONG-TERM BREAST CANCER SURVIVORS

EHA Library, Jorge Illarramendi Esteban, 420686

REDUCED DOSE FLAG-MITOXANTRONE AND LOW DOSE VENETOCLAX INDUCES DEEP REMISSIONS AND HIGH RATE OF TRANSITION TO SUCCESSFUL ALLOGENEIC STEM CELL TRANSPLANTATION INRELAPSED/REFRACTORY AML

EHA Library, Ahmad Ibrahim, 420687

EFFICACY OF VENETOCLAX IN COMBINATION WITH STANDARD INTENSIVE (3+7) INDUCTION IN ADULT ACUTE MYELOID LEUKEMIA – EARLY RESULTS FROM A REAL-WORLD EXPERIENCE.

EHA Library, Akash Kumar, 420688

BASELINE GENOMIC TESTING AND OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THE MODERN ERA: REAL-WORLD DATA FROM A LARGE US COHORT

EHA Library, Xin Wang, 420689

CLINICAL OUTCOMES OF CONCURRENT FLT3 INHIBITOR AND IDH INHIBITOR THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Catherine Gutierrez Moore, 420690

CHEMOTHERAPY-FREE CONSOLIDATION IS EQUALLY EFFECTIVE AS CHEMOTHERAPY-INCLUSIVE APPROACHES IN HIGH-RISK APL PATIENTS POST-REMISSION INDUCTION

EHA Library, Fangyi Dong, 420691

RICHTER SYNDROME DIFFUSE LARGE B-CELL LYMPHOMA TYPE: PHENOTYPIC CHARACTERIZATION AND COMPARATIVE ANALYSIS WITH THE ORIGINAL CLL AND WITH DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS

EHA Library, Fernando Martin Moro, 420692

ACSL1 PROMOTES FERROPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA VIA DUSP6/ERK PATHWAY

EHA Library, Xin Wang, 420693

ASSOCIATION BETWEEN GENOMIC ALTERATIONS AND SERUM MONOCLONAL PROTEINS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Juan Antonio Pineyroa Gigosos, 420694

FOXO1-MEDIATED CELL CYCLE ARREST AND APOPTOSIS IS INHIBITED BY USP7 DOWNSTREAM OF BCR LIGATION IN CLL CELLS.

EHA Library, Hassan Almuhanna, 420695

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) PATIENT DEMOGRAPHICS AND PATIENT-REPORTED BURDEN IN IBRUTINIB AND NON-IBRUTINIB RECEIVERS IN THE US: A REAL-WORLD STUDY.

EHA Library, Zaina Qureshi, 420696

ADVANCED CYTOGENOMIC APPROACHES FOR PRECISE RECONSTRUCTION OF COMPLEX KARYOTYPE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Sabina Adamová, 420697

EXPLORING THE RELATIONSHIP BETWEEN KARYOTYPE COMPLEXITY AND DNA METHYLATION IN UNMUTATED IGHV CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Stella Charalampopoulou, 420698

A CX3CR1 (FRACTALKINE RECEPTOR) SMALL MOLECULE ANTAGONIST (KAND567) SUPPRESSED THE GROWTH-PROMOTING EFFECT OF NURSE-LIKE CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Wen Zhong, 420699

JAK3-STAT5 SIGNALING IS INVOLVED IN SHAPING THE IMMUNE INHIBITORY PHENOTYPE OF T HELPER CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Shimrit Ringelstein-Harlev, 420700

RESISTANCE MECHANISMS ASSOCIATED TO ONE-CARBON METABOLISM INHIBITION IN B-CELL MALIGNANCIES

EHA Library, Chloé Duculty, 420701

BIOENGINEERED SMALL EXTRACELLULAR VESICLES AS INNOVATIVE IMMUNOTHERAPIES IN CLL

EHA Library, Lucie Rospape, 420702

GLUTAMINE ADDICTION IN THE CLL MICROENVIRONMENT; TOWARDS IMPROVED DETECTION WITH PET IMAGING

EHA Library, Helga Simon-Molas, 420703

PREVALENCE AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Samir Mouhssine, 420704

FUNCTIONAL PHENOTYPE MODEL PREDICTS PROGRESSION FREE SURVIVAL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON141/VISION TRIAL

EHA Library, Weikaixin Kong, 420705

PRELIMINARY ANALYSIS OF THE COMPLEX PROJECT: IMPACT OF GENOMIC COMPLEXITY IN CLL PATIENTS TREATED WITH TARGETED THERAPIES IN A REAL-LIFE SETTING

EHA Library, Silvia Ramos-Campoy, 420706

IMMUNE CELL EFFECTS OF LONG-TERM ACALABRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Olina Lind, 420707

ΝON-MUTATIONAL MYC ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: FROM TRANSCRIPTOMICS TO CLINICOBIOLOGICAL ASSOCIATIONS

EHA Library, Maria Tsagiopoulou, 420708

SINGLE-CELL SEQUENCING OF IN VITRO 3D CLL MODEL PROVIDE INSIGHT INTO INTERACTIONS WITHIN THE CLL LYMPH NODE NICHE UPON TREATMENT WITH BTK INHIBITORS

EHA Library, Marco Haselager, 420709

ANALYSIS OF MUTATIONS IN BTK AND BCL2 WITH CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS SUGGESTS DIFFERENT RESISTANCE MECHANISMS AND SUBCLONAL DYNAMICS UNDER TREATMENT WITH BTK OR BCL2 INHIBITORS

EHA Library, Miguel Bastos Boente, 420710

DIETARY INFLUENCES ON CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION: UNVEILING THE POTENTIAL OF EARLY-STAGE INTERVENTION

EHA Library, Maike Buchner, 420711

LIVE CLL CELLS INSIDE THE BONE MARROW FIBROBLASTS AND ITS IMPLICATION IN DISEASE PERSISTENCE

EHA Library, Y. Lynn Wang, 420712

MUTATIONAL STATUS OF KAPPA AND LAMBDA LIGHT CHAIN GENES INDEPENDENTLY PREDICTS TIME TO FIRST TREATMENT IN EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jana Nabki, 420714

REAL-WORLD USE AND EFFECTIVENESS OF ACALABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: THE NATIONAL ACALABRUTINIB OBSERVATIONAL STUDY (NAOS)

EHA Library, Anne Quinquenel, 420715

REAL LIFE EVIDENCE OF THE USE OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A REGISTRY STUDY ON BEHALF OF THE SPANISH CLL GROUP (GELLC)

EHA Library, Alberto Lopez García, 420716

PRELIMINARY SAFETY AND EFFICACY RESULTS FROM A PHASE 1B STUDY OF ORAL NON-COVALENT BTK INHIBITOR AS-1763 IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES

EHA Library, Nitin Jain, 420717

REAL-WORLD OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH BTK INHIBITORS (BTKI): A SUBGROUP ANALYSIS OF OVER 1100 PATIENTS ENROLLED INTO THE GIMEMA CLL2121 STUDY

EHA Library, Lydia Scarfò, 420718

PHASE I TRIAL OF A PERSONALIZED MULTI-PEPTIDE VACCINE COMBINED WITH THE TLR1/2 LIGAND XS15 UNDER BRUTON-TYROSINE-KINASE INHIBITOR (BTKI) TREATMENT IN CLL PATIENTS

EHA Library, Susanne Jung, 420719

PIRTOBRUTINIB IN RELAPSED/REFRACTORY CLL/SLL: RESULTS FROM BTKI NAÏVE COHORT IN THE PHASE 1/2 BRUIN STUDY

EHA Library, Toby Eyre, 420720

TARGETED THERAPIES ERADICATE THE NEGATIVE PROGNOSTIC IMPACT OF IGHV SUBSET#2 IN CHRONIC LYMPHOCYTIC LEUKEMIA : A RETROSPECTIVE REAL-LIFE MULTICENTER FRENCH STUDY

EHA Library, Lucile Bussot, 420721

TIME TO NEXT TREATMENT AFTER FIRST-LINE TREATMENT WITH TIME-LIMITED TARGETED AGENTS: A POOLED ANALYSIS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITHIN CLINICAL TRIALS OF THE GCLLSG

EHA Library, Nadine Kutsch, 420722

REAL-WORLD CARDIOVASCULAR AND CLINICAL OUTCOMES IN PATIENTS INITIATING COVALENT BTK INHIBITORS (CBTKI) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE UNITED STATES

EHA Library, Hayden Hyatt, 420723

A CLINICAL PHASE II STUDY ON INTERMITTENT AND REPEATED DOSING (“ON-OFF-REPEAT”) OF IBRUTINIB TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jeanette Lundin, 420724

IMPACT OF VENETOCLAX-BASED THERAPIES ON AUTOIMMUNE CYTOPENIAS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER STUDY CONDUCTED BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL

EHA Library, Marta Coscia, 420725

FEASIBILITY OF VENETOCLAX-BASED REGIMENS IN 110 OCTOGENARIAN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTER ITALIAN STUDY

EHA Library, andrea serafin, 420726